Qazi Corner Videos

Qazi reviews findings from a study exploring the safety of endoscopic retrograde cholangiopancreatography in the early versus late post-transplant period.

Qazi reviews findings from a study exploring potential causes of seronegative villous atrophy, emphasizing the importance of maintaining a broad differential in diagnosis.

Qazi discusses implications from a recent study exploring the impact of post-IPAA cuffitis on long-term pouch outcomes and the risk of developing strictures and fistulas.

Qazi reviews findings from a recent study suggesting glucagon does not have a significant impact on esophageal foreign body impaction resolution.

Qazi discusses the impact of bariatric surgery on outcomes in patients with decompensated cirrhosis, highlighting its benefit in this patient population.

Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.

Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.

Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.

Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.

Shubha Bhat, PharmD, MS, BCACP describes the ELEVATE UC program supporting the FDA approval of etrasimod and the current understanding of treatment positioning between etrasimod and ozanimod.

Data support the benefit of bariatric surgery in patients at high risk of pancreatic ductal adenocarcinoma due to BMI and metabolic comorbidities.

Qazi reviews an analysis of an EHR-assisted smoking cessation module that could improve conversations between specialists and patients.

While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.